PDCD1 and neoplasm: PD-1 inhibitors (nivolumab, pembrolizumab) specifically bind to the PD-1 receptor on T cells, block the interaction of PD-L1 and PD-L2 ligands on tumor cells with PD-1, and restore suppressed T cell function to activate anticancer immune responses [118].